Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT® trial

Citations of this article
Mendeley users who have this article in their library.


Background: Gender differences may occur in many chronic diseases. We have examined the influence of gender in chronic obstructive pulmonary disease (COPD) on long-term responses to tiotropium. Methods: Subgroup analysis of data from the Understanding the Potential Long-term Impact of Tiotropium (UPLIFT®) trial (4-year, randomized, double-blind, placebo-controlled trial of tiotropium in patients with COPD). Results: Of 5992 patients, 75% were men and 25% women. Mean age was 65 and 63 years, respectively. Baseline post-bronchodilator forced expiratory volume in 1 s (FEV1) = 47% predicted(men) and 49% predicted(women). St George's Respiratory Questionnaire (SGRQ) total score was 44.9 and 48.7 units, respectively. At 48 months, improvement in trough FEV 1 over control was 92 mL(men) and 77 mL(women) (p < 0.001 for both), with no differences in the rate of decline (trial primary endpoint). Hazard ratio (HR) (95% confidence interval [CI]) for first exacerbation (tiotropium/placebo) was 0.87(0.81, 0.93)(men) and 0.83(0.74, 0.94)(women). Number of exacerbations (per patient-year) was reduced with tiotropium in men (from 0.82 to 0.71) and women (from 0.92 to 0.77) (p < 0.005 for both). HR (95% CI) for a hospitalized exacerbation was 0.89(0.79, 0.99) and 0.77(0.62, 0.94), respectively. HR (95% CI) for mortality during treatment was 0.85(0.72, 0.99)(men) and 0.85(0.62, 1.18)(women). Improvements in SGRQ total score (tiotropium-control) at 1, 2, 3 and 4 years were: -2.8, -2.3, -3.6, -2.4(men) and -2.7, -2.6, -2.6, -2.1(women) (p < 0.05 for all). Conclusion: Long-term treatment of COPD with tiotropium improves lung function, exacerbations and health status in men and women, with similar magnitudes of benefit. © 2010 Published by Elsevier Ltd.

Author supplied keywords




Tashkin, D., Celli, B., Kesten, S., Lystig, T., & Decramer, M. (2010). Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT® trial. Respiratory Medicine, 104(10), 1495–1504. https://doi.org/10.1016/j.rmed.2010.03.033

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free